Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Treatment	STARTED	Sorafenib + C/P	464
Treatment	STARTED	Placebo + C/P	462
Treatment	Received Treatment	Sorafenib + C/P	463
Treatment	Received Treatment	Placebo + C/P	459
Treatment	COMPLETED	Sorafenib + C/P	91
Treatment	COMPLETED	Placebo + C/P	88
Treatment	NOT COMPLETED	Sorafenib + C/P	373
Treatment	NOT COMPLETED	Placebo + C/P	374
Follow-up	STARTED	Sorafenib + C/P	354
Follow-up	STARTED	Placebo + C/P	369
Follow-up	COMPLETED	Sorafenib + C/P	176
Follow-up	COMPLETED	Placebo + C/P	174
Follow-up	NOT COMPLETED	Sorafenib + C/P	178
Follow-up	NOT COMPLETED	Placebo + C/P	195

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00300885/flow